StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) income statement

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.66−0.11 (-14.51%)

Close on Nov 16, 2026Market cap $119.13MP/E –Yield –

Compass Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-41.3%

Financial strength

Current ratio
11.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
219.8%

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.72
Dividend yield
–

See a number that looks wrong?